Placebo-Controlled Pilot Trial of Mecamylamine for Treatment of Autism Spectrum Disorders

Completed · Phase 1 · Has a placebo group

Conditions studied: Autistic Disorder, Pervasive Developmental Disorder

In brief

The purpose of this study is to examine the safety and efficacy of mecamylamine for the core symptoms of autism.

Key facts

Study ID

NCT00773812

Run by

Ohio State University

People needed

20

Starts

2007-07-01

Expected to finish

2012-11-01

Last updated by the study team

2017-01-13

Who can join

Age: 4 and older, up to 12. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Autistic Disorder or Pervasive Developmental Disorder-Not Otherwise Specified
• Age 4-12
• General good health
• IQ of >=36 or mental age of >=18 months
• Parent/caregiver willingness to accompany child to clinic and monitor for side effects

You may not qualify if…

• Unstable Seizure Disorder
• Psychoactive medication in the process of adjustment
• Antipsychotic medication in previous 3 months before baseline
• Systemic corticoids (inhalers allowed)
• Planned beginning of major behavioral intervention in 3 months of study or the 2 months prior to the study.

Where it is running

• Nisonger Center — Columbus, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.